Optimism On ICDs: St. Jude And Boston Scientific Exceed Expectations
This article was originally published in The Gray Sheet
St. Jude Medical reported strong cardiac rhythm management results in the second quarter and said it picked up market share, but struggling competitor Boston Scientific refused to recoil, announcing U.S. ICD sales losses that were about half what was expected
You may also be interested in...
Boston Scientific is banking on intense communication with physicians and new product launches to eventually pull its ICD business back to its pre-sales-suspension standing, but the firm acknowledges that it will be playing catch-up for the foreseeable future
Boston Scientific resumed shipments of virtually all of its implantable defibrillators April 15 following retrospective clearance by FDA of two manufacturing changes
Following hot on the heels of its Rapidly Manufactured Ventilator Specification document, the UK’s regulator has issued another speedy regulatory permit for fast production of respiratory assist devices.